F-18 FDG PET/MRI findings of primary breast lymphoma in two cases

Kong, Eun Jung; Cho, Ihn Ho

doi:10.1016/j.clinimag.2015.01.015

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These neoplasms can arise from lymphatic tissue adjacent to ducts and lobules, from intramammary lymph nodes and, least frequently, from mucosa-associated lymphoid tissue (4). Most breast lymphomas are diffuse large B-cell (DLBCL) which account for 56% to 84% as in our cases, followed by marginal zone lymphoma (9-28%), follicular lymphoma (10-19%) and Burkitt lymphoma (<5%) (3,4,5). In women with breast implants there is a higher incidence of anaplastic large cell lymphoma (ALCL), which ranges between 0.1 -0.3 per 100.000 cases (6).…”

mentioning

confidence: 66%

“…At MRI masses are solid, circumscribed, without desmoplastic reaction, showing high or mild heterogeneous internal enhancemen (9,10). Recent nuclear medicine techniques such as PET/MRI can show high 18F-FDG uptake in multinodular enhancing masses and have the advantage of accurately determine the extension of the disease (5). Differential diagnoses include primary breast cancer, phyllodes tumor, fibroadenoma and metastatic disease (11,12).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Primary Breast Lymphoma: Report of 2 Cases and Review of the Literature.

Murad¹

2019

IJAR

View full text Add to dashboard Cite

mentioning

confidence: 66%

mentioning

confidence: 99%

Primary Breast Lymphoma: Report of 2 Cases and Review of the Literature.

Murad¹

2019

IJAR

View full text Add to dashboard Cite

“…Molybdenum target X-rays rarely show adverse manifestations such as burr sign and infundibulum sign [ 9 , 11 ]. Systemic PET-CT is not only helpful in the diagnosis of PB-DLBCL, but also has high specificity in the evaluation of systemic involvement, treatment effect and recurrence of patients [ 14 , 15 ]. Due to non-specific clinical and imaging manifestations and low incidence of PB-DLBCL, this patient was initially misdiagnosed with breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Primary Breast Diffuse Large B-Cell Lymphoma in a 42-Year-Old Female: A Case Report and Review of Literature

Chen

Zhou

2021

J Med Cases

View full text Add to dashboard Cite

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare localized extranodal lymphoma. It is mainly diagnosed by pathological examination due to the lack of specific clinical and imaging manifestations. Whole-body positron emission tomography-computed tomography (PET-CT) is widely used in determining clinical staging and guiding clinical treatment. As part of comprehensive treatment, targeted therapy with rituximab, intrathecal methotrexate injection and consolidation radiotherapy remain controversial in treating PB-DLBCL, but the comprehensive treatment based on full-course of chemotherapy is still widely used as the first-line treatment. Comprehensive treatment often leads to a sharp decline in the immunity of elderly patients with malignancy. In this situation, surgery may be a good chance to improve their life quality without serious complications. We present a rare case of PB-DLBCL during the coronavirus disease 2019 (COVID-19) pandemic. The patient underwent chest CT scan to screen COVID-19 and a mass of left breast was accidentally found. Because of the city lockdown policy in Wuhan, she did not seek medical help until noticing that the mass was gradually enlarged. Both ultrasonography and mammography indicated that the lesion was breast cancer. However, ultrasound-guided core needle biopsy revealed diffuse large B-cell lymphoma of breast and PET-CT scan showed that the lesion was a primary hypermetabolic tumor of left breast. The patient subsequently received comprehensive treatment based on six cycles of rituximab-cyclophosphamide, hydroxydaunomycin, oncovin, prednisone (R-CHOP) chemotherapy.

show abstract